One Biosciences

Executive Summary

One Biosciences is a Paris-based AI-driven startup transforming single-cell genomics by making it clinically actionable. Traditional bulk sequencing masks cellular heterogeneity, but One Biosciences' proprietary platform resolves complexity at single-cell resolution using widely available FFPE or frozen samples. Their end-to-end solution delivers high-quality single-cell maps and clinician-ready reports in under two weeks—a significant improvement over current timelines. The platform is validated across multiple tumor types, indicating robust performance in oncology applications. By combining AI with a streamlined workflow, One Biosciences aims to democratize single-cell analysis for real-world clinical use, enabling precision medicine, biomarker discovery, and drug development. The company, founded in 2019, is privately held with no disclosed funding, positioning it as an early-stage but promising player in the rapidly expanding single-cell and precision oncology markets. Its ability to work with FFPE samples, which are standard in pathology archives, gives it a unique edge over competitors that require fresh or flash-frozen tissue. With growing demand for high-resolution molecular profiling in clinical settings, One Biosciences is well-positioned to capture value as it scales. However, given its private status and lack of public financial data, conviction is tempered by execution risk and the need for commercial validation.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round65% success
• Q4 2026Strategic Partnership with Pharma or Diagnostic Company40% success
• Q2 2026Clinical Validation Study Publication70% success